Short Interest of The Day: What’s Propelling Athersys Incorporated (NASDAQ:ATHX) After Higher Shorts Reported?

November 24, 2016 - By Louis Casey   ·   0 Comments

Short Interest of The Day: What’s Propelling Athersys Incorporated (NASDAQ:ATHX) After Higher Shorts Reported?

The stock of Athersys Incorporated (NASDAQ:ATHX) registered an increase of 7.33% in short interest. ATHX’s total short interest was 6.76M shares in November as published by FINRA. Its up 7.33% from 6.30 million shares, reported previously. With 308,600 shares average volume, it will take short sellers 22 days to cover their ATHX’s short positions. The short interest to Athersys Incorporated’s float is 8.15%. The stock increased 0.57% or $0.01 on November 23, hitting $1.75. About 311,413 shares traded hands. Athersys, Inc. (NASDAQ:ATHX) has declined 26.16% since April 22, 2016 and is downtrending. It has underperformed by 31.57% the S&P500.

Athersys, Inc. is an international biotechnology firm that is focused primarily in the field of regenerative medicine. The company has a market cap of $143.84 million. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. It currently has negative earnings. The Company’s clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insitutional Activity: The institutional sentiment decreased to 0.83 in 2016 Q2. Its down 1.31, from 2.14 in 2016Q1. The ratio turned negative, as 12 funds sold all Athersys, Inc. shares owned while 10 reduced positions. 23 funds bought stakes while 24 increased positions. They now own 14.56 million shares or 52.63% more from 9.54 million shares in 2016Q1.
Sabby Mgmt Limited Com holds 91,746 shares or 0.01% of its portfolio. Legal And General Group Plc last reported 0% of its portfolio in the stock. Glenmede Trust Co Na holds 0% or 21,500 shares in its portfolio. Kcg Inc has invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). State Common Retirement Fund owns 77,600 shares or 0% of their US portfolio. Blackrock holds 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX) for 2,968 shares. Airain Ltd owns 10,921 shares or 0% of their US portfolio. Goldman Sachs Grp Inc Inc holds 0% or 507,232 shares in its portfolio. Teachers holds 0% or 118,912 shares in its portfolio. Wells Fargo Mn has 32,885 shares for 0% of their US portfolio. The Ontario – Canada-based Manufacturers Life Insur Com The has invested 0% in Athersys, Inc. (NASDAQ:ATHX). Private Advisor Grp Inc Llc has 14,168 shares for 0% of their US portfolio. Intll Grp Incorporated Inc has invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Citigroup Inc, a New York-based fund reported 8,070 shares.

Insider Transactions: Since September 15, 2016, the stock had 0 insider purchases, and 2 sales for $35,323 net activity. 3,000 Athersys, Inc. (NASDAQ:ATHX) shares with value of $5,874 were sold by Lehmann William JR. Harrington John J had sold 15,000 shares worth $29,449 on Thursday, September 15.

ATHX Company Profile

Athersys, Inc., incorporated on June 7, 2005, is an international biotechnology firm that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. The Company’s activities consist primarily of research and product development activities. The Company’s clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. MultiStem treatment enhances tissue repair and healing in multiple ways, including reducing inflammatory damage, protecting tissue that is at risk following acute or ischemic injury, and promoting formation of new blood vessels in regions of ischemic injury. These cells appear to be responsive to the environment in which they are administered, by homing to sites of injury and/or organs involved in injury response, and providing active disease response, while producing proteins that may provide benefit in both acute and chronic conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>